MedTrace Logo

Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients

NCT05286242 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-04-25

No results posted yet for this study

Summary

The purpose of this study is to understand the immune response to coronavirus disease-19 (COVID-19) vaccination in patients on B-cell depleting therapies (BCDT) over time, which in the future may help to inform clinical decision making in this patient population.

Conditions

Interventions

BIOLOGICAL

COVID19 vaccine

All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Robert Leet and Clara Guthrie Patterson Trust

    collaborator UNKNOWN

  • Yale University

    lead OTHER

Principal Investigators

  • Erin Longbrake · Yale University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2026-05-31
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05286242 on ClinicalTrials.gov